Effectiveness, Cognitive Safety and Pharmacoeconomic Analysis of PCSK9 Inhibitors in Clinical Practice

Abstract

PCSK9 inhibitors and LDL reduction play a crucial role in cardiovascular disease (CVD) management, significantly improving health outcomes. This thesis explores key areas: the impact of the COVID-19 pandemic on cholesterol control in patients using PCSK9 inhibitors; the long-term safety of these inhibitors, especially on cognitive function; and the cost- effectiveness of additional lipid-lowering therapies in patients already on PCSK9 inhibitors. Groundbreaking findings include the maintained efficacy and safety of PCSK9 inhibitors during the pandemic; the safe use of dapagliflozin in non-vaccinated patients, however, it demonstrated an increased risk of infection; no significant impact on cognitive functions by PCSK9 inhibitors even in those achieving very low LDL-C levels during follow-up across various studied domain